Detalhe da pesquisa
1.
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
Antiviral Res
; 206: 105403, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041646
2.
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
Antimicrob Agents Chemother
; 53(2): 646-50, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19015353
3.
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Antimicrob Agents Chemother
; 53(2): 662-9, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19015343
4.
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
Antivir Ther
; 10(5): 635-43, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16152757
5.
Long-acting injectable antiretrovirals for HIV treatment and prevention.
Curr Opin HIV AIDS
; 8(6): 565-71, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24100877